-
公开(公告)号：US20230095167A1
公开(公告)日：2023-03-30
申请号：US17801469
申请日：2021-02-19
Applicant: Universiteit Maastricht , Academisch Ziekenhuis Maastricht , Roche Diagnostics Operations, Inc.
Inventor： Alfred Engel , Michael Gerg , Ute Jucknischke , Johann Karl , Peter Kastner , Thomas Meier , Lars Hillringhaus , Ulrich Schotten , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen , André Ziegler , Roberto Latini , Jennifer Marie Theresia Anna Meessen
Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP10 in a sample from the subject, and comparing the amount of BMP10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP 10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP10-type peptide in a sample from a subject. The present invention further pertains to antibodies which bind to one or more BMP10-type peptides such as NT-proBMP10.
-
公开(公告)号：US11466098B2
公开(公告)日：2022-10-11
申请号：US16740778
申请日：2020-01-13
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Bernhard Eckert , Michael Gerg , Johann Karl , Martin Kaufmann , Julia Riedlinger , Magdelena Swiatek-de Lange , Lars Hillringhaus , Klaus Hirzel , Marcus-Rene Lisy
IPC: C07K16/36 , G01N33/574 , G01N33/86
Abstract: The present disclosure relates to specific binding agents binding to different PIVKA-II forms as compared to antibodies known so far in the art. The present disclosure also relates to methods of using the specific binding agents to detect the presence of PIVKA-II.
-
公开(公告)号：US20200371114A1
公开(公告)日：2020-11-26
申请号：US16721112
申请日：2019-12-19
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Roberto Latini , Serge Masson , Dirk Block , Christian Zaugg , Thomas Dieterle , Edelgard Kaiser , Johann Karl , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen
IPC: G01N33/68
Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.
-
公开(公告)号：US10557858B2
公开(公告)日：2020-02-11
申请号：US15581587
申请日：2017-04-28
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Roberto Latini , Serge Masson , Dirk Block , Christian Zaugg , Thomas Dieterle , Edelgard Kaiser , Johann Karl , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen
Abstract: Described is a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from B-type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-proBNP), IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject along with the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy.
-
公开(公告)号：US10345315B2
公开(公告)日：2019-07-09
申请号：US15274533
申请日：2016-09-23
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Johann Karl , Ursula-Henrike Wienhues-Thelen , Dirk Block , Christian Zaugg , Hans-Peter Brunner , James Januzzi , Andre Ziegler , Julian Braz , Thomas Dieterle , Edelgard Kaiser
Abstract: Disclosed herein is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Also disclosed is a method of monitoring diastolic function in a patient suffering from heart failure, and kits and devices for performing the method.
-
Patent Agency Ranking
公开(公告)号：US20150192587A1
公开(公告)日：2015-07-09
申请号：US14463975
申请日：2014-08-20
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Norbert Wild , Ursula Garczarek , Andrea Geistanger , Herbert Andres , Marie-Luise Hagmann , Johann Karl , Friedemann Krause , Michael Pfeffer , Wolfgang Rollinger , Michael Tacke , Michael Thierolf
IPC: G01N33/574
CPC classification number: G01N33/57419 , C12Q1/6886 , G01N2333/4727 , G01N2333/805 , G01N2333/8146 , G01N2333/9121
Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein S100A12 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring S100A12 in said sample. Measurement of S100A12 can, e.g., be used in the early detection or diagnosis of colorectal cancer.
-
公开(公告)号：US20140219998A1
公开(公告)日：2014-08-07
申请号：US14251788
申请日：2014-04-14
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Markus Roessler , Johann Karl , Julia Riedlinger , Ingo Lindner , Michael Tacke
IPC: G01N33/574
CPC classification number: G01N33/57488 , G01N33/57423 , G01N33/57484 , G01N2333/475 , G01N2800/52
Abstract: Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Further disclosed is a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in the sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
Abstract translation: 披露了一种有助于评估癌症的方法。 更具体地公开了在早期肿瘤蛋白（= ARMET）中转移的精氨酸富集作为不同癌症类型的通用标记物的用途。 ARMET有助于评估肺或肺癌（LC）或结肠癌，例如非小细胞肺癌（NSCLC）或结肠直肠癌（CRC），但也可能是其他特定类型的癌症。 这些特定的癌症类型是例如乳腺，卵巢，子宫颈，头颈部，子宫内膜，黑素瘤，膀胱，肾，胰腺，前列腺，食管，胃或胆管癌。 进一步公开了一种通过测量样品中的ARMET从个体获得的来自液体样品的癌症的方法。 例如，可以将ARMET的测量用于癌症的早期检测或用于进行手术的患者的监视。
-
公开(公告)号：US20240272154A1
公开(公告)日：2024-08-15
申请号：US18616550
申请日：2024-03-26
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Herbert Andres , Johann Karl , Ursula Kunert , David Morgenstern , Nina Meissler , Marion Niessner , Magdalena Swiatek-de Lange
IPC: G01N33/564 , C07K16/46 , G01N33/574
CPC classification number: G01N33/564 , C07K16/46 , G01N33/574 , G01N33/5748 , G01N33/57496
Abstract: An in vitro method is disclosed for detecting an antibody to p53 (anti-p53 antibody) in a sample, the method comprising: incubating a sample to be analyzed with a p53 capture antigen and a p53 detection antigen, whereby a complex comprising the p53 capture antigen, the anti-p53 antibody and the p53 detection antigen is formed, separating the complex formed from unbound detection antigen and measuring the complex obtained via the detection antigen comprised therein, thereby detecting the anti-p53 antibody comprised in the sample.
-
公开(公告)号：US11971407B2
公开(公告)日：2024-04-30
申请号：US17730403
申请日：2022-04-27
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Herbert Andres , Johann Karl , Ursula Kunert , David Morgenstern , Nina Meissler , Marion Niessner , Magdalena Swiatek-de Lange
IPC: G01N33/53 , C07K16/46 , G01N33/564 , G01N33/574
CPC classification number: G01N33/564 , C07K16/46 , G01N33/574 , G01N33/5748 , G01N33/57496
Abstract: An in vitro method is disclosed for detecting an antibody to p53 (anti-p53 antibody) in a sample, the method comprising: incubating a sample to be analyzed with a p53 capture antigen and a p53 detection antigen, whereby a complex comprising the p53 capture antigen, the anti-p53 antibody and the p53 detection antigen is formed, separating the complex formed from unbound detection antigen and measuring the complex obtained via the detection antigen comprised therein, thereby detecting the anti-p53 antibody comprised in the sample.
-
公开(公告)号：US20220252592A1
公开(公告)日：2022-08-11
申请号：US17730403
申请日：2022-04-27
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Herbert Andres , Johann Karl , Ursula Kunert , David Morgenstern , Nina Meissler , Marion Niessner , Magdalena Swiatek-de Lange
IPC: G01N33/564 , G01N33/574 , C07K16/46
Abstract: The disclosure relates to an in vitro method for detecting an antibody to p53 (anti-p53 antibody) in a sample, the method comprising: incubating a sample to be analyzed with a p53 capture antigen and a p53 detection antigen, whereby a complex comprising the p53 capture antigen, the anti-p53 antibody and the p53 detection antigen is formed, separating the complex formed from unbound detection antigen and measuring the complex obtained via the detection antigen comprised therein, thereby detecting the anti-p53 antibody comprised in the sample.
-
-
-
-
-
-
-
-
-
Search Results
41
records
(took 0.028 seconds)
